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Abstract  
Post-translational modification (PTM) is a modification of a protein after its translation. This 
modification can occur either by the covalent addition of particular chemical groups or by 
enzymatic cleavage of peptide bond. Post-translational modifications play an important role in 
signaling pathways, protein stability, oxidative regulation of proteins and cellular localization. 
Variations of the modification sites can highly affect or disrupt these important biological 
processes and can lead to disease. The aim of this study was to analyze the variation sites of 
post-translational modification sites and their relation to disease.   
Experimentally verified post-translational modifications were downloaded from Human Protein 
Reference Database (HPRD) web site. The Single-nucleotide Polymorphism (SNP) data, which 
contains both pathogenic and neutral missense variations, were matched against the post-
translational data to filter out Post-translational Modifications (PTMs) in variation sites. 
DRUMs, WAVe and Locus specific databases were used to separate disease-causing variations, 
which occur at the PTM sites. To study the conservation of the variation sites ConSurf was used 
and a statistical analysis was done by using hyper geometric distribution and t- test.  
Disease causing variations were found in both pathogenic and neutral datasets. The conservation 
score of disease causing variation has indicated that they are more conserved than the benign 
variations. To further study the variation sites of PTM one can investigate the gene function of 
PTMs in order to understand which molecular and cellular functions are disrupted by disease 
causing variations.  
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1 ITRODUCTIO  
The interest in analyzing protein modifications and their effect in cell biology and pathogenesis 
has made human proteome and system biology the most important field of study (Tejaswita and 
Amrita, 2011). The structure of a protein plays a big role in its functionality and chemical 
alternations of proteins after translation, which is known as post-translational modifications, 
have a great significance to the structural and functional diversity of the proteins (Li et al., 2010).  
These modifications can be caused by covalent addition of chemical groups to the amino acid 
side chain or by cleavage of the peptide bond. And all this changes have consequences in the cell 
function, in the activity state, localization and turnover of the protein itself.    
Over the years many studies related to the importance of post-translational modifications have 
been done. For example, in one study it mentions that the importance of glutathionylation 
(oxidative PTM) in directly regulating human glyoxalase 1 (Glo1) which is cystolic enzyme that 
catalyze the conversion of toxic α-oxo-aldehydes into the corresponding α-hydroxy acids using 
L-glutathione (GSH) as a cofactor (Birkenmeier et al., 2010). In another study post-translational 
modification of lysine residues at the tumor suppressor P53 C terminus plays an important role in 
regulating the stability and activity of P53 (Olsson et al., 2007).   
When a post-translational modification site is affected by variation the role may change and 
become a threat to health. The variations could be loss or gain of the modifications site due to 
substitution of amino acid residues. Systematic studies have been done by the help of databases 
containing disease-causing variations by relating post-translational modification to disease. It 
was stated in one research that protein phosphorylation predominantly occurs within intrinsically 
disordered protein regions (Lilia et al., 2004). Vogt et al. looked into the gain of N-linked 
glycosylation sites and their involvement in disease predicting that a number of disease 
associated mutations introduce changes in glycosylation patterns by creating NX[ST] motifs 
(Vogt et al., 2005; Vogt et al., 2007). Also in another research gain and loss of phosphorylation 
target sites may be an active mechanism in human cancer (Radivojac et al., 2008). 
This study was done to analyze the distribution of post-translational modification sites in disease 
causing variations and to see the conservation of amino acid residues in both disease causing 
variations and post-translational modification sites. In general the study analyzes the influence of 
disease causing variations on post-translational modification sites.  
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2 LITERATURE REVIEW  
2.1 Post-translational modification  
The human genome is estimated to encode 20,000 to 25,000 protein-coding genes. This number 
has been revised many times through the years. And the total number of proteins in the human 
proteome is around 1 million (Jensen et al., 2004). As it can be seen from this number one gene 
can encode multiple proteins. This makes the human proteome complex and the complexity is 
further facilitated by post-translational modifications (Li et al., 2010).   
 
 
Post-translational modification (PTM) is a chemical process that occurs after the translation of a 
protein. It can be reversible or irreversible. (Li et al., 2010).Enzymes are involved in order to the 
PTM to occur some of the enzymes are Phosphatases , kinases, transferase and ligases . Post-
translational modification has two major modification categories. The first one is covalent 
modification which is the addition of chemical groups such as phosphorly, acetyl or glycosyl to 
the amino acid side chains and the second one is the cleavage of peptide bond by the enzyme 
called Proteases (protein hydolases). (Walsh et al.,2006) 
There are more than 200 types of PTM the majority of this post-translational modifications occur 
by the addition of chemical groups to their amino acid chain for example phosphorylation is one 
of the most well studied and important  type of PTM. It occurs at the side chain of three amino 
acids Serine(S), threonine(T)  and tyrosine (Y). they are phosphorylated by Kinase. (Radivojac et 
al., 2008)  
Discovering of Post-translational modifications 
Source: http://www.piercenet.com/browse.cfm?fldID=7CE3FCF5-0DA0-4378-A513-2E35E5E3B49B 
FIGURE 1 Post-translational modification and proteomic diversity. 
Knowing post-translational modification is important as it is a well-known fact but they are not 
discovered as often as possible because of the lack of suitable methods. In previous years PTMs 
have been identified using various methods such as Edman degradation, amino acid analysis, 
isotopic labeling or immunochemistry (Mann and Jensen, 2003). 
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2.2 Detection of post-translational modifications by tandem mass spectrometry  
The identification of the protein is the first step in PTM analysis. After identifying the protein it 
will be compared to a known amino acid sequence  
When a protein undergoes post-translational modification the presence of covalent modification 
changes the molecular weight of the modified amino acid and this can be detected by tandem 
mass spectrometry (MS/MS) which involves multiple steps of mass spectrometry. MS has plenty 
of advantages over the other methods such as it is very sensitive, it has a great ability to identify 
PTM sites and it identifies PTM in complex mixture of proteins (Larsen et al., 2006). 
By using chemical reagents or proteases the protein can be converted to peptides because 
peptides are more amenable to MS and MS/MS. Ionization of the peptide will help to determine 
the exact weight of the peptide. 
As shown in figure 2 to detect PTMs by using tandem mass spectrometry first the ion source 
which contain the ionized peptide will go under MS survey scan to analyze the mass (the first 
MS) then by using the mass-to-charge ratio (m/z) value the peptide ion of interest can be 
separated. In order to activate the separated peptide ion species collision-induced dissociation 
(CID) is used this will pass on internal energy to the ions and activate their fragmentation. Then 
the m/z values of the fragments are determined by mass spectrometry (the second MS) (Larsen et 
al., 2006). This collection of fragment ion reveals the sequences of the amino acids (Steen and 
Mann, 2004). 
The fragment ion signals reflect the amino acid sequence as read from either the N-terminal (b-
ion series) or the C-terminal (y-ion series) direction. By determining the mass difference between 
b-ion series or y-ion series it is possible to identify the individual amino acids (Roepstorff and 
Fohlman, 1984).  
Knowing the exact mass difference is significant in order to describe what types of modifications 
are present. By comparing the experimentally obtained molecular mass with the calculated 
amino acid sequence of the protein mass will determine any mass increment. The mass 
increment is caused by the covalently attachment of chemical groups for example 
phosphorylation (+80Da) and nitration (+45 Da). And the other scenario that causes mass 
difference is the hydrolytic cleavage of the peptide bond which leads to mass deficit (Larsen et 
al., 2006).  
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Source: http://www.biotechniques.com/multimedia/archive/00002/BT._A_000112201_O_2231a.pdf 
FIGURE 2. Tandem mass spectrometry (MS/MS) for mapping post-translational modifications 
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2.3 Types of PTM 
2.3.1 Phosphorylation 
Phosphorylation is one of the most common and well-studied types of modification. It plays a 
vital role in regulating protein function and transmitting signals throughout the cell. 
The enzymes that catalyze the protein phosphorylation are the largest class of post-translational 
modification enzymes and they are called kinases. It is estimated that there are more than 500 
kinases in human genome (Walsh et al., 2005).  
Phosphorylation happens when a phosphate group is added to serine, threonine or tyrosine. 
When the amino acids attack the terminal phosphate group (Y-PO3
 2- )
 on ATP (adenosine 
triphosphate) with their nucleophilic (-OH) group the magnesium (Mg
2+
) will facilitate the 
phosphate group to transfer to the amino acid side chain. Figure 2.3 below shows serine 
phosphorylation. The (-OH) group of serine facilitates nucleophilic attack of γ-phospehate group 
on ATP which results the transfer of phosphate group to serine forming phosphoserin and ADP. 
Source: http://www.piercenet.com/browse.cfm?fldID=4E12BA00-5056-8A76-4E40-CD0254A2E35 
FIGURE 3. The diagram of serine phosphorylation  
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2.3.1.1 Phosphorylation in bacteria  
Bacteria proteins are involved in serine/threonine specific phosphorylation. These modifications 
are associated with secondary metabolism, oxidative stress response and sporulation (Cozzone et 
al., 2005). Phosphates and serine/threonine kinases are also involved in bacterial virulence. 
The first tyrosine phosphorylation was discovered in Escherichia coli (E.coli) (Manai and 
Cozzone, 1982). Capsule production, growth, proliferation and migration are some of the 
essential cellular process that are directed by protein tyrosine phosphorylation (Zhang et al., 
2005). The enzyme that catalyzes bacterial tyrosine phosphorylation is bacterial tyrosine (BY) 
kinases. BY kinases can function in two ways, as anchor and intercellular catalytic domain 
(Grangeasse et al., 2007). In its structure it contains walker A (P- loop) and B motif. BY kinases 
regulate the synthesis and secretion of polysaccharides through posphorylation and activation of 
UDP sugar dehydrogenases and glucosyltransferases (Stulke et al., 2010). The 
dephosphorylation of tyrosyl-phosphorylated protein is catalyzed by bacterial tyrosine 
phosphatases. 
2.3.1.2 Phosphorylation in plant 
Proteins in plant undergoes through reversible phosphorylation. Protein phosphorylation occurs 
as a response to many signals including pathogen invasion, temperature stress and nutrient 
deprivation.  
In mid 1998 around 500 plant protein kinases have been discovered. In Arabidopsis thaliana 
alone there are 175 protein kinases. Based on the article published by Hanks and Hunter in 1995 
the four major families of plant protein kinases are ACG group, CaMK group, CMGC group and 
conventional PTK group. Cell growth, gene expression and sensing environment conditions are 
controlled by network of protein serine/threonine kinases. (Hardie et al.,1999).  
The dephosphorylation of proteins is catalyzed by protein phosphatase. In plant protein 
phosphatase activity has been reported in sub cellular compartment including mitochondria, 
chloroplast, nuclei and cytosol (Huber et al., 1994 and Mackintosh et al., 1991).    
2.3.2 Glycosylation 
Glycosylation is a process when a protein is attached to carbohydrate group (sugar moieties) by 
glycosidic bonds. Based on there glycosidic linkages there are five types of glycosylation. 
1. -linked glycosylation: as the name implies N- glycosylation occurs when glycans 
are covalently bound to the carboxamido nitrogen on asparagines (Asn or N) 
residues (ionsource.com). Even if N-glycosylation is grouped as type of post-
translational modification it often happens co-translationally when the protein is 
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being translated not after the translation. N-linked glycosylation happens in the ER. 
(Thermo scientific)  
2. O-linked glycosylation: it occurs between monosaccharide N- acetylgalactosamine 
and the hydroxyl group of amino acids serine or threonine (ionsource.com). O-
linked glycosylation occur in ER, Golgi, cystosol and nucleus (Thermo scientific).   
3. Glypiation (GPI anchors): it occurs when a protein is linked to a phospholipid by 
glycan core (Thermo scientific).   
4. C-linked glycosylation: when mannose residue covalently attached to tryptophan 
residue C-linked glycosylation occurs (Uniport, 2011). It differs from other types of 
glycosylation because the reaction forms carbon-carbon bond not carbon-nitrogen or 
carbon-oxygen bond like the others do (Thermo scientific). 
5. Phosphoglycosylation: occurs when phosphodiester bond binds glycan to serine. It 
is common in parasites and slim molds. 
 
Source: http://www.piercenet.com/browse.cfm?fldID=4E12331D-5056-8A76-4E72-1C5A427505F1 
FIGURE 4 Types of glycosylation  
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2.3.2.1 Glycosylation in bacteria  
Before it was believed prokaryotes are not able to synthesize glycoprotein, many studies have 
shown proof to the contrary (Benz and Schmidth, 2002). The first protein glycosylation 
discovered in prokaryotes is in archaea which has a glycosylated surface layer (S-layer) protein 
(Hitchen et al., 2006).  
Bacteria proteins can undergo both N-linked and O-linked glycosylation (Harald et al., 2010). In 
2003, more than 70 bacterial glycoproteins were reported (Szymanski et al., 2003). Most of the 
glycoproteins that are present in bacteria are surface or secreted proteins this means that they 
affect how the bacteria interact with the environment (Schmidt et al., 2003). For example 
glycoproteins in Escherichia coli bacteria are secreted as autotransporters. These proteins are 
family of outer membrane proteins which are involved in toxication, invasion and aggregation. 
Glycoproteins are glycoslated by the addition of heptoses (Klemm et al., 2006).     
2.3.2.2 Glycosylation in yeast 
Both N-linked and O-linked glycosylation occur in yeast. Animal cell and yeast N-linked 
glycosylation are identical in their initial stage. However, O-linked glycosylation in yeast is 
different from higher eukaryotes.  
N-linked glycosylation starts in endoplasmic reticulum (ER). The first step is the transfer of 
dolichol-bound precursor oligosaccharide Glc3Man9GlcNAc2 to nascent polypeptide by the help 
of enzyme called oligosaccharyltransferase. The glucose sugar that is found on oligosaccharide 
branch is removed by glucosidase I and glucosidase II. The removal of the glucose sugar will 
initiate a process called glycan-mediated chaperoning. If there are glycoproteins leaving the ER 
with different structure due to misfolding they will be reglycoslated and transported in to cytosol. 
Therefore this process is useful for quality control. Mannose sugars and mannosylphosphate 
transferases are added on the resulting Man8GlcNAc2-containing glycoprotein (Mochizuku et 
al., 2001 and Lehle et al., 1992) 
2.3.3 Methylation  
Methylation occurs in two ways, the first one is when one carbon methyl groups transfer to 
nitrogen (N-methylation) and the second one is when it is transferred to oxygen (O-methylation). 
The residues that are methylated on nitrogen include Є-amine of lysine, the imidazole ring of 
histidine, the guanidine moiety of arginine and the side chain of amide nitrogens of glutamine 
and asparagines. (Lee et al., 2005) 
Histone lysine methylation occurs on histone H3 and histone H4. Lysine 4, 8, 14, 27, 36 and 79 
are methylated in histone H3 and lysine 20 and 59 in histone H4 (Strahl and Allis, 2000). Lysine 
methyltransferases (KMTs) and lysine demethylases are the two enzymes which add or remove 
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methylation mark on lysine residues respectively (Zhang et al., 2012). The enzymes involved in 
lysine methylation were believed to be only histone specific but with enough evidence it has 
been found that they are not histone specific. For example the first non-histone protein 
methylation that was reported was methylation of p53 by KMT7. Most histone lysine 
modifications are involved in activation or repression of transcription (Lee et al., 2005).  
 
Source: http://www.atdbio.com/content/56/Epigenetics#Histone-methylation 
FIGURE 5. Lysine methylation mechanism, Mechanism of methylation of lysine by histone 
lysine methyltransferases (KMTs) 
The above figure shows the conversion of S-adenosyl-L-methioine (AdoMet) which is the source 
of the methyl group in to S-adenosyl-L-homocysteine (AdoHcy)  
Arginine methylation is common in eukaryotes (Bedford et al., 2007). It is found on both nuclear 
and cytoplasmic proteins. Protein arginine N-methyltransferase (PRMT) is the enzyme that 
catalyzes methylation of arginine (Bedford and Richard, 2005). Methylation of arginine plays 
important role in regulating protein-protein interaction, transcriptional regulation and signal 
transduction. Both histone and arginine methylations are irreversible (Lee et al., 2005). 
There are indication that methylation is useful in protecting proteins in two ways. By blocking 
sites of ubiquitination it prevents from protein degradation and methylation reaction repair 
damaged protein molecules Mathews and Christopher, 2000).  
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2.3.4 -Acetylation 
Acetylations occur for two specific biological purposes. The first one is in eukaryotic proteins 
acetylation occurs at N- terminal co transitionally and the other is acetylation of histones and 
transcriptional factors which affects chromatin structure and selective gene transcription (Walsh 
et al., 2006).   
N-terminal acetylation occur after the cleavage of the N-terminal methionine by methionine 
aminopeptidase (MAP) the amino acid is replaced by acetyl group which is acetyl-CoA by using 
the enzyme called N-acetyltransferase (NAT) and the histone acetylation occur at Є-NH2 of 
lysine on histone N-termini. Generally acetylation plays a great role in cell biology (Walsh et al., 
2006). 
2.3.4.1 Acetylation in bacteria  
Acetylation is catalyzed by the enzyme N-acetyltransferase (NAT). There are three types of NAT 
termed NatA, NatB and NatC.  
Bacterial acetylation occurs on NЄ group of bacterial protein. Protein acetylation has been 
considered as eukaryotic phenomenon. Everything that is known about bacterial acetylation 
came from two proteins: the central metabolic enzyme ACS and the signaling protein CheY (Hu 
et al., 2010). ACS is controlled by reversible acetylation of single lysine residue. Reversible 
phosphorylation of aspartate and reversible acetylation of multiple lysine residues controls the 
ability of signaling protein CheY. 
 
 
Source: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2958.2010.07204.x/full 
FIGURE 6: Reversible acetylation of ACS and CheY 
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In figure 6 reversible acetylation of ACS acetyl –CoA is used as acetyl donor. NAD
+
 is used for 
deacetylation of ACS also CheY can be acetylated by ACS or some other acetyltransferases (AT) 
and the deacetylation is catalyzed by CobB.  
2.3.5 Proteolytic cleavage  
When the peptide bond between amino acids breaks proteolytic cleavage occur. The enzymes 
that carry out this process are called peptidases or proteases (CLC Bio et al., 2005). These 
enzymes can be classified in two groups the first one is based on their site of action when a 
single amino acid is removed from the termini (exopeptidases) and when internal peptide bond is 
cleaved (endopeptidases). The second is based on the nature of active site residues involved in 
mechanism. These are serine proteases, cysteine proteases, aspartyl proteases and zinc (metallo) 
proteases (Walsh et al., 2006).  
Proteases act on protein substrate due to various reasons some of them are mentioned below  
• After translation when N-terminal methionine residues are removed.  
• Cleavage of proteins or peptides in order to be used as nutrients.  
• During translocation when signal peptides are removed through membrane.  
Proteolytic cleavage plays a diverse biological role such as signal transduction, proliferation, 
homeostasis, blood coagulation and fibrinolysis (Walsh et al., 2006). 
2.4 Biological significance of PTMs 
Rapid growth in understanding proteome has increased the knowledge of proteins. Also the focus 
on post-translational modifications and their effect on protein function have given a new insight 
in changes that are caused by post-translational modifications. For example signaling pathway 
from membrane to nucleus involves a series of protein modifications in response to external 
stimuli (Seo and Lee, 2012).  
PTMs have greater importance because of their involvement in supervising gene expression, 
activation/ deactivation of enzymatic activity, protein stability or distraction and mediation of 
protein-protein interaction. Below Table 1 shows the function of post-translational modifications, 
the modification site and the amino acid residue change (Walsh et al., 2006).  
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TABLE 1 Biological function of post-translational modifications  
PTM Type Modified amino 
acid residues  
Position  Effects  
Acetylation  S 
K 
N-term 
Anywhere 
Protein stability, regulation of 
protein functions 
Phosphorylation Y,S,T,H,D Anywhere Regulation of protein activity, 
signaling  
Cys oxidation 
 disulfide bond 
 glutathionylation 
 sulfenic acid 
 sulfinic acid 
 
C 
C 
C 
C 
 
Anywhere 
Cell proliferation, differentiation  
Acylation 
 farnesylation 
 myristoylation 
 
 palmitoylation 
 
C 
G 
K 
C(S,T,K) 
 
Anywhere 
N-term 
Anywhere 
Anywhere 
 
Cellular localization to 
membrane 
Glycosylation 
 O-linked 
 (O-Glc-NAc) 
 N-linked 
 
S,T 
 
N 
Anywhere Cell-cell interaction and 
regulation of protein  
Methylation 
 monomethylation 
 dimethylation 
 trimethylation 
 
K 
K 
K 
Anywhere Regulation of gene expression, 
protein stability  
Nitration 
S-Nitrosylation 
Y 
C 
 Regulation of gene expression, 
protein stability  
Ubiquitination 
Sumoylation 
K 
K 
Anywhere 
[ILFV]K.D 
Signal transduction, DNA repair  
Hydroxyproline 
Pyroglutamic acid 
P 
Q 
 
N-term 
Protein stability  
 
Source: http://bmbreports.org/jbmb/jbmb_files/%5B37-1%5D0401271834_035-044.pdf 
2.5 Variation of post-translational modification sites and disease  
Variations are changes in DNA and RNA. They play a vital role in human proteome. Changes in 
protein conformation that leads to enzymes that are non-functioning or differently functioning 
and unusual protein structure can be a result of variation. For example Duchenne muscular 
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dystrophy is an inability to produce dystrophin protein. The lack of this protein cause abnormal 
or no cell structure organization and Huntington's disease is a progressively deterioration of the 
nervous system caused by abnormal proteins. So we can conclude that variations are a cause of 
many human diseases. Also variation affects post-translational modification sites (Li et al., 
2010). 
There have been studies about the variations of post translational modification and their 
contributions to human disease. Some of these studies are mentioned below. 
• In prion protein (PrP) gene a heterozygous T183A has undergone mutation which has 
resulted the removal of N-linked glycoslation of PrP. This variation was detected in a 
patient with spongiform encephalopathy. Some of the symptoms are early-onset dementia 
as the predominant sign, along with global cerebral atrophy and hypometabolism there 
are also neurological signs which occur at late stage of the disease including cerebellar 
ataxia and EEG abnormalities (Grasbon et al., 2004).  
• On androgen receptor acetylation occur on lysine residue the loss of this acetylation site 
has been linked to Kennedy’s disease which is inherited neurodegenerative disorder. The 
variation of lysine residues at 630, 632 and 633 to alanine markedly delays ligand-
dependent nuclear translocation in androgen receptor (Thomas et al., 2004). 
• Familial advanced sleep phase syndrome (FASPS) is caused by variation in binding 
region of hPER2 casein kinase Iepsilon (CKIepsilon) from serine to glycine at a 
phosphorylation site (Toh et al., 2001).   
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3 OBJECTIVES  
The main objective of this study was to analyze the variations at post-translational modification 
and their relevance to diseases. There are two groups in the PTM sites with variations disease 
causing variations and not disease causing variations. By considering this  
• Analyze if certain types of PTMs have been enriched or depleted in the two groups  
• Study how well the variations at PTMs are conserved  
17 
 
4 MATERIALS AD METHOD  
4.1 Materials  
In this study two data sets were used the single nucleotide polymorphism data set and the data 
downloaded from human protein reference database (HPRD) which contains 93,710 
experimentally verified PTM sites.    
The SNP data set contain a total of 32,003 variations of which 14,610 were pathogenic variations 
and 17,393 were neutral missense variations. The missense pathogenic variations were built from 
PhenCode database (Giardine et al., 2007) (downloaded in June 2009), registries in IDbases 
(Piirilä et al., 2006) and from 18 individual LSDBs. The neutral missense variations are obtained 
from dbSNP database (Sherry et al., 2001]) build 131. 
4.1.1 Databases 
The following tools were used to analyze the data. 
• DRUMS:  is a search engine for human disease related genetic variations. It collects the 
genotype – phenotype data from LSDBs and makes it available for users.  
• WAVe: is a web-based application that integrates locus specific databases and gathers 
available genomic variations in a single working environment.  
• Locus specific mutation database: this database is available on HGVS website.  
• ConSurf: a bioinformatics tool used for estimating conservation of amino acid in 
proteins.  
• UniProtKB:  it contains a collection of proteins with their functional information. 
 4.2 Methods  
4.2.1 Filtering the SP data set  
The SNP data were matched with the experimentally verified post-translational modification 
sites in order to separate the variants which have undergone post-translational modification. 
python script was made to do the matching.  
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4.2.2 Matching post translational modifications with amino acid substitutions 
By filtering the SNP data a set of human post-translational modifications have been created. 
With the purpose of investigating the relationship between post-translational modification and 
amino acid substitution exact matching has been done in the sites were the substitution occurred 
at a modification sites. 
4.2.3 Disease related and not disease related variations  
As mentioned above the SNP data set contains two kinds of variation the pathogenic and neutral 
missense variations. In each of these variations the position which the amino acid substitution 
occur have been analyzed to see if this variations are disease related at this exact position. In 
order to accomplish this, three databases such as Locus Specific Mutation Database, DRUMS 
and WAVe were used. The databases were searched manually for each variation.  
4.2.4 Conservation score analysis  
The position-specific conservation score for the variants were calculated using the ConSurf 
server. First by using CSI-BLAST close homologous sequences were obtained then a multiple 
alignment was constructed using MAFFT. Bayesian method was used in calculating the position 
specific conservation score. The conservation score values have nine scales from one to nine one 
being the least conserved (Ashkenazy et al., 2010). 
4.2.5 Statistical analysis  
In the statistical analysis Excel and R programs were used. The statistical methods that were 
applied are hyper geometric distribution and T-test. 
4.2.5.1 Hypergeometric distribution  
Hypergeometric distribution is a probability distribution of the number of successes in a hyper 
geometric experiment. In hyper geometric experiment the researcher select randomly without 
replacement from a finite population and every item in the population can be categorized as 
success or failure. 
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The Hypergeometric formula is: 
h (x;N,n,k) = [kCx] [N-KCn-x] / [NCn]          /1/ 
Notations  
 N: The number of items in the neutral and pathogenic variation dataset. 
 k: The number of items in the neutral and pathogenic variation dataset that are classified 
as successes. 
 n: The number of items in the sample . 
 x: The number of items in the sample that are classified as successes. 
 kCx: The number of combinations of k things, taken x at a time. 
 h(x; N, n, k): hypergeometric probability - the probability that an n-trial hypergeometric 
experiment results in exactly x successes, when the neutral and pathogenic variation 
dataset  consists of N items, k of which are classified as successes. 
Suppose let’s say 84 variants were selected randomly without replacement from disease causing 
data set. What is the probability of getting exactly 37 variants which has phosphorylation site? 
By using R the hypergeometric distribution was calculated. This will show if certain types of 
PTMs are depleted or enriched in any of the two datasets. 
The hypergeometric tests were done by comparing the 32,003 variations (the primary variation 
data) with both the disease related and not disease related variations.  
4.2.5.2 T-test 
To compare the means of disease related variations and not-disease related variations the T-test 
was used  
Assumptions 
• the distribution of the variants are normal  
• samples are independent  
• they have equal variance 
The sample size of the two data sets were different by calculating the ratio of two data set and 
multiplying one data set with ratio normalization was done to make the total number equal.  
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Null Hypothesis: 
The type of variation (disease or not disease related) has no effect on the type of post-
translational modifications.  
Alternative Hypothesis: 
The type of variation (disease or not disease related) has effect on the type of post-translational 
modifications  
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5 RESULTS  
5.1 Variations with post-translational modification sites  
There were a total of 32,003 variations which include pathogenic and neutral variations. By 
matching the post-translational dataset and variation data set 35,103 variations with both PTM 
sites and variation site were found. From the 28 types of post-translational modifications found 
more than half were a phosphorylation modification. 
TABLE 2 Types and total number of post-translational modification with variation sites 
Post-translational 
modification  
Total number of 
sites 
Post-translational 
modification 
Total number of 
sites 
Phosphorylation  28,191 Carboxylation 25 
Acetylation 1951 Prenylation 14 
Glycosylation   1852 Myristoylation 22 
Proteolytic cleavage 1053 Transgutamination 8 
Disulfide Bridge 1214 Glycosyl  11 
Dephosphorylation  206 Nitration 20 
Farnesylation 2 Amidation 8 
Methylation 94 Glutathionylation 6 
SUMOylation 145 Neddylation 9 
Palmitoylation 78 Hydroxylation 10 
S- Nitrosylation 46 Alkylation 5 
Sulfation 24 ADP Ribosylation 7 
Ubiquitination 58 Deacetylation 4 
Glycation 39 Deacylation 1 
 
5.2 Amino acid substitutions  
From 35,103 variations with post-translational modification the number of amino acid 
substitution that lie directly on the modification site are 242 and from this 96 were pathogenic 
variations and 146 were neutral variations. 
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FIGURE 7. The distribution of PTMs in the neutral variation data set  
 
FIGURE 8. The distribution of PTMs in pathogenic variations 
5.3 Mutations of post-translational modification sites                                                              
The 242 proteins which have post-translational modification sites have also undergone through 
mutation which is single nucleotide polymorphism. From this variants it was found that in the 
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neutral variation data set categories which include 146 variation 58 of them were found to be 
disease causing, 19 of them are not related to any disease and for the 69 variations no 
information were obtained in any of the database used on their relation to disease. In the case of 
pathogenic variations from 96 variations 84 were found to be disease related, 1 variation was not 
related to any disease and on 11 variations there were no information obtained about their 
relation to any disease.  
TABLE 3 Total summaries of neutral and pathogenic variations and their relation to disease   
 Disease causing  Not disease causing  No information  
Neutral Variations  58 19 69 
Pathogenic Variations  84 1 11 
 
For conservation score and statistical analysis two categories of variations were chosen   
• Disease causing variations from pathogenic data set, and  
• From neutral variation not disease causing variation plus the variation which no   
information has been obtained are added together and considered as benign variations.  
 
FIGURE 9. The distribution of PTMs in disease causing variations 
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FIGURE 10. The distribution of PTMs in benign variations   
5.4 Conservation of post-translational modification sites  
From ConSurf server analysis the conservation score of both disease and benign variation has 
been obtained.  In disease causing variation 69 variations (82.15%) are highly conserved, 10 
variations (11.90%) are average and 5 variations (5.95%) are not conserved or they are variable. 
 
FIGURE 11. The distribution of conservation score in disease causing variations   
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For benign varations 35 varations (39.8%) are found to be not conserved, 21 varations (23.9%) 
are average and 32 varations (36.4%) are highly conserved as shown below in table  
 
FIGURE 12. The distribution of conservation score in benign variations   
5.5 Hypergeometric test result  
As it can be seen from the table below the hypergeometric distribution was calculated for disease 
causing variations and benign variations. In the table the hyper geometric probability P(X=x) 
was calculated which shows if certain types of PTMs are enriched or depleted in any of the 
categories.   
TABLE 4. Hypergeometric distributions of disease causing and benign variations  
Diseases causing variations Benign variations  
Types of PTM N K n X P(X=x) N K n X P(X=x) 
Phosphorylation 35103 28191 84 37 1.74e-13 35103 28191 88 63 0.014 
Proteolytic 35103 1053 84 15 2.43e-08 35103 1053 88 4 0.147 
Methylation 35103 94 84 1 0.181 35103 94 88 0 0.789 
Acetylation 35103 1951 84 1 0.041 35103 1951 88 5 0.181 
Glycosylation 35103 1852 84 4 0.196 35103 1852 88 4 0.191 
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Carboxylation 35103 25 84 8 7.95e-16 35103 25 88 0 0.94 
Disulfide 35103 1214 84 18 4.26e-10 35103 1214 88 7 0.022 
Glycation 35103 39 84 0 0.911 35103 39 88 5 4.68e-
08 
The above table shows the hypergeometric probability P(X=x) of disease causing variations and 
benign variations. Form the result shown in Table 4 most of the PTMs in disease causing 
variations are enriched except glycation. This can be viewed on figure 13 the red bars indicates 
the hyper geometric probability P(X=x) of disease causing variation and the blue ones indicate 
the hyper geometric probability P(X=x) of benign variations. For example the value of P(X=x) 
for glycation in benign variations is so small that it cannot be seen on the diagram.   
 
FIGURE 13. Hypergeometric distribution of disease causing variations and benign variations 
data   
5.6 T-test result    
Table 6 shows the data used to calculate the t-test in benign variations column the values stated 
are the normalized value. The t-test has given a p-value of 0.9997 which is greater than the 
significance level this will indicate the data in this study may not be sufficient enough to reject 
the null hypothesis.  
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TABLE 6. Total numbers of PTMs in both diseases related and not disease related variations  
Post-translational 
modifications  Disease related Benign variations  
Phosphorylation 37 60.14 
Proteolytic 15 3.82 
Glycation 0 4.78 
Acetylation 1 4.78 
Glycosylation 4 3.82 
Disulfide 18 6.69 
Methylation 1 0 
Carboxylation 8 0 
 
Two Sample t-test 
data:  a and b  
t = -4e-04, df = 14, p-value = 0.9997 
alternative hypothesis: true difference in means is not equal to 0  
95 percent confidence interval: 
 -18.06656   18.05906  
Sample estimates: 
Mean of x mean of y  
10.50000   10.50375 
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6 DISCUSSIOS  
Post-translational modifications are crucial in changing physiochemical properties of proteins. 
These alternations often may result initiation of important process such as gene expression, 
oxidative regulation of protein and cell-to-cell interaction. The function of such biological 
process becomes interrupted when the modification sites become mutated. This study has 
analyzed the post-translational modification sites and disease associated variations that occur on 
the modification sites. 
In this study, neutral and pathogenic variations which have undergone post-translational 
modification have been analyzed. It was found that in both variation groups phosphorylation has 
the highest percentage as seen in Figure 7 and 8. 
There have been incidents in which variation of post-translational modification sites are involved 
in disease. Both neutral and pathogenic variations were evaluated and it was found that from the 
pathogenic variations 87.5% of the variations are diseases causing and from the neutral variation 
only 39.8% were disease related.  
When analyzing the conservation score of disease causing and benign variations first the protein 
sequence in fasta format is submitted to ConSurf server. The result is a text document which 
includes the conservation score of each amino acid. As it can be seen in Figures 11 and 12 the 
disease causing variations were more conserved than the benign variations. 
The hyper geometric distribution test has revealed that methylation, glycosylation and 
acetylation are enriched in disease causing variations. This may indicate that disease-causing 
variations are more likely to affect post-translational modifications than benign variations. 
The p-value obtained from the t-test were 0.9997 which is greater than the significance level 
(0.05) this indicates that the data may not be sufficiently persuasive to reject the null hypothesis 
which states the type of variation (disease or not disease related) has no effect on the type of post 
translational modifications.  
There have been studies which have analyzed variations at PTM sites. A study carried out by 
Radivojac and his colleague’s who analyzed gain and loss of phosphorylation sites have 
concluded that the variations at the phosphorylation sites are more likely a mechanism in cancer. 
In another study Li et al. looked in to the loss of PTM sites in disease and have found that 
disease causing variation were highly conserved (Li et al., 2010). 
Because of the data used in this study there may be problems that lead to ascertainment bias. The 
first one is the variation data which contains post-translational sites is heavily skewed towards 
phosphorylation which is more than 50%. The reason behind this could be phosphorylation has 
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been discovered more frequently than the other post-translational modifications because of 
discovery techniques like mass spectrometry has been effective and its high influence on 
biological processes has also played a big role. The second problem can arise from the variations 
which are not disease causing. This data may probably contain undiscovered disease mutations.   
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7 COCLUSIOS  
The main objective of this study was to investigate post-translational modification sites and their 
effect on disease. Based on this from the 242 modification sites which contain 96 pathogenic 
variations and 146 neutral variations the disease causing variation has been filtered   out by the 
help of biological data bases like DRUMs, WAVe, locus specific database and locus specific 
mutation database. 84 variations form pathogenic variation and 58 variations form neutral 
variations were found to be disease-causing variants. The other objective of the study was to see 
the distribution of post-translational modification sites in both disease causing and benign 
variations. Histograms, hyper geometric test and t-test were used to do the statistical analysis. 
Finally to see how these modification sites were conserved ConSurf were used to calculate the 
conservation score. 
The result of this study indicated that the disease associated mutations that occur in modification 
sites change the protein functions by disrupting the post-translational modification sites. It was 
found that 87.5% of the pathogenic variants and 39.8% of neutral variations are disease causing.  
From this one can conclude that post-translational modifications are not the major cause of 
disease. It was also found that disease causing variations are highly conserved. The hyper 
geometric test has shown which type of post-translational modifications are enriched or depleted 
in disease and benign variations. 
A further study could assess the following points for example this study has shown that in neutral 
variations category from 146 variations 58 variations were disease causing and for the 69 
variations in this category there were no information found on any of the databases used about 
their relation to disease this indicates that further study can be done to find more about this 
specific variations. And another point to see further will be what kind of molecular and cellular 
functions were disrupted because of the disease causing variations.   
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9 APPEDICES  
TABLE 7. Disease causing variations  
Gene symbol Residue change Modifications Conservation Score  
APP L705V Proteolytic 9 
APP A713T Proteolytic 9 
APP  T714A Proteolytic 9 
APP T714I Proteolytic 9 
APP D694N Proteolytic 7 
BRCA1 R1204I Phosphorylation 7 
BRCA1 S1217Y Phosphorylation 9 
BRCA1 S1187I Phosphorylation 2 
BRCA1 P1150S Phosphorylation 8 
BRCA1 R866Q Glycosylation 9 
BRCA1 G960D Phosphorylation 4 
CTNNB1 S45F Phosphorylation 9 
CTNNB1 S45P Phosphorylation 9 
CTNNB1 S33F Phosphorylation 9 
CTNNB1 S33L Phosphorylation 9 
CTNNB1 S33Y Phosphorylation 9 
CTNNB1 S37C Phosphorylation 9 
CTNNB1 S37F Phosphorylation 9 
CTNNB1 S37Y Phosphorylation 9 
CTNNB1 S37A Phosphorylation 9 
CTNNB1 T41A Phosphorylation 9 
CTNNB1 T41I Phosphorylation 9 
COL2A1 G909C Proteolytic 9 
COL2A1 G981S Proteolytic 9 
EDN3 Y127C Proteolytic 9 
FGFR1 C277Y Proteolytic 9 
FUS R244C Methylation 8 
GH1 Q117L Phosphorylation 7 
MAPT S622N Phosphorylation 9 
MPZ K236E Phosphorylation 4 
NFKBIA S32I Phosphorylation 9 
RAF1 T491I Phosphorylation 9 
RAF1 T491R Phosphorylation 9 
RAF1 S259A Phosphorylation 9 
RAF1 S259F Phosphorylation 9 
RAF1 S257L Phosphorylation 9 
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RAF1 T260R Phosphorylation 8 
PRNP E196K Glycosylation 5 
PROC E62A Carboxylation 9 
PTPN11 Y62D Phosphorylation 2 
PTPN11 Y63C Phosphorylation 6 
PTPN11 T2I Acetylation 5 
MECP2 Y120D Phosphorylation 6 
BTK Y361C Phosphorylation 7 
EMD S54F Phosphorylation 7 
GLA N215S Glycosylation 7 
FGD1 S205I Phosphorylation 1 
F9 E79D Carboxylation 6 
F9 E53A Carboxylation 9 
F9 E54G Carboxylation 9 
F9 E66V Carboxylation 9 
F9 E67) Carboxylation 9 
F9 E73K Carboxylation 9 
F9 E73V Carboxylation 9 
F9 R191C Proteolytic 2 
F9 R191H Proteolytic 2 
F9 R226G Proteolytic 9 
F9 R226Q Proteolytic 9 
F9 R226W Proteolytic 9 
F9 C134Y Disulfide 9 
F9 C155F Disulfide 9 
F9 C170F Disulfide 9 
IDS N115Y Glycosylation 9 
DNM2 S619L Phosphorylation 7 
DNM2 S619W Phosphorylation 7 
FGF23 R179Q Proteolytic 6 
EDNRB S305N Phosphorylation 4 
KCNJ1 S219R Phosphorylation 9 
HSPB1 S135F Phosphorylation 9 
RHO C110F Disulfide 9 
RHO C110Y Disulfide 9 
AGA C163S Disulfide 6 
NDP C39R Disulfide 8 
NDP C65W Disulfide 8 
NDP C69S Disulfide 8 
NDP C65Y Disulfide 8 
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HAMP  C70R Disulfide 8 
FSHB C69G Disulfide 9 
AGA C306R Disulfide 8 
NDP C96W Disulfide 8 
NDP C96Y Disulfide 8 
NDP C110G Disulfide 8 
NDP C110R Disulfide 8 
HAMP C78Y Disulfide 8 
 
TABLE 8. Benign variations  
Gene symbol Position aa Modifications Conservation score  
BGLAP 94 R Proteolytic 7 
DSG2 903 T Phosphorylation 5 
AHSG 256 T Glycosylation 1 
HBB 2 V Glycation 8 
HBB 9 K Glycation 7 
HBB 9 K Glycation 7 
IGF2R 1107 T Phosphorylation 6 
IGF1 115 A Proteolytic 1 
LMNA 10 T Phosphorylation 1 
PTPRC 191 N Glycosylation 4 
SPP1 224 S Phosphorylation 2 
DDX5 480 S Phosphorylation 1 
SEMG1 372 R Proteolytic 4 
CD180 430 T Phosphorylation 9 
AKR7A2 255 S Phosphorylation 1 
PDLIM5 136 S Phosphorylation 3 
EML4 978 S Phosphorylation 1 
PDCD6IP 730 S Phosphorylation 1 
CCDC99 508 Y Phosphorylation 1 
HBB 73 S Phosphorylation 3 
HBB 5 T Phosphorylation 5 
ITIH2 60 S Phosphorylation 3 
KRT8 26 T Phosphorylation 1 
LMNA 22 S Phosphorylation 9 
LMNA 588 S Phosphorylation 5 
LMNA 583 S Phosphorylation 8 
MDH2 301 K Acetylation 3 
MBD1 505 T Phosphorylation 8 
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NF1 2502 S Phosphorylation 1 
CTTN 87 K Acetylation 4 
SPP1 210 S Phosphorylation 9 
PAM 860 S Phosphorylation 7 
ARID4A 864 S Phosphorylation 9 
RPLP0 285 T Phosphorylation 1 
RANBP2 1118 S Phosphorylation 1 
DOCK1 1857 T Phosphorylation 2 
ADD3 651 S Phosphorylation 5 
ADD3 650 S Phosphorylation 4 
HIP1 35 S Phosphorylation 7 
CTAGE5 647 S Phosphorylation 2 
ABLIM1 578 Y Phosphorylation 1 
FOXM1 658 T Phosphorylation 9 
TRA2B 95 S Phosphorylation 7 
RAD51AP1 326 K Acetylation 7 
ATRN 1185 T Phosphorylation 4 
EIF4B 462 S Phosphorylation 9 
LMO7 1182 S Phosphorylation 8 
LMO7 663 S Phosphorylation 7 
AKAP13 808 S Phosphorylation 9 
PAK2 20 S Phosphorylation 9 
PAK2 2 S Phosphorylation 5 
TACC2 151 T Phosphorylation 7 
HSD17B7 321 K Acetylation 3 
TJP2 1012 S Phosphorylation 4 
TJP2 1010 Y Phosphorylation 3 
GNL3 478 S Phosphorylation 3 
NCAPD2 1325 Y Phosphorylation 1 
PHLDB2 252 Y Phosphorylation 4 
CTR9 943 S Phosphorylation 4 
ZNF267 424 T Phosphorylation 5 
ZWILCH 85 T Phosphorylation 2 
L1TD1 548 T Phosphorylation 4 
PHACTR4 131 S Phosphorylation 1 
TTC19 6 T Phosphorylation 6 
ORAI1 223 N Glycosylation 1 
CC2D1A 92 T Phosphorylation 3 
ZNF768 83 S Phosphorylation 6 
MKI67 2720 T Phosphorylation 4 
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SRGAP1 1001 T Phosphorylation 2 
PLEKHA5 382 S Glycosylation 6 
VWF 2754 C Disulfide 9 
SERPING1 205 C Disulfide 9 
IFNGR1 85 C Disulfide 8 
VWF 1130 C Disulfide 9 
VWF 1458 C Disulfide 9 
VWF 2804 C Disulfide 9 
VWF 804 C Disulfide 9 
HBB 9 K Glycation 7 
HBB 131 Y Phosphorylation 1 
HBB 131 Y Phosphorylation 1 
HBB 145 K Acetylation 3 
HBB 67 K Glycation 8 
AHSG 340 R Proteolytic 2 
ACE 716 T Phosphorylation 1 
CAPN3 417 T Phosphorylation 8 
CAPN3 345 S Phosphorylation 1 
CSF1 461 S Phosphorylation 4 
EPB41 410 S Phosphorylation 9 
  
 
 
 
 
 
 
 
